Document is current
Any future updates will be listed below
-
Authors
Gadd, Danni A.
Smith, Hannah M.
Mullin, Donncha
Chybowska, Ola
Hillary, Robert F.
Kimenai, Dorien M.
Bernabeu, Elena
Cheng, Yipeng
Fawns-Ritchie, Chloe
Campbell, Archie
Page, Danielle
Taylor, Adele
Corley, Janie
Del C. Valdés-Hernández, Maria
Maniega, Susana Muñoz
Bastin, Mark E.
Wardlaw, Joanna M.
Walker, Rosie M.
Evans, Kathryn L.
McIntosh, Andrew M.
Hayward, Caroline
Russ, Tom C.
Harris, Sarah E.
Welsh, Paul
Sattar, Naveed
Cox, Simon R.
McCartney, Daniel L.
Marioni, Riccardo E.
-
Funding
Funding for this research was provided by:
Wellcome Trust (108890/Z/15/Z, 218493/Z/19/Z, 104036/Z/14/Z, 104036/Z/14/Z, 104036/Z/14/Z, 221890/Z/20/Z)
Medical Research Council
British Heart Foundation Intermediate Basic Science Research Fellowship (FS/IBSRF/23/25161)
Alzheimer's Society (AS-PG-19b-010, AS-PG-19b-010)
Scottish Health Research Register and Biobank
Scottish funding council (HR03006, HR03006, HR03006)
Chief Scientist Office of the Scottish Government Health Directorate (CZD/16/6, CZD/16/6, CZD/16/6)
UK Dementia Research Institute Ltd which is funded by the Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK Institute (award no. UKDRI – Edin002, DRIEdi17/18, and MRC MC_PC_17113)
The University of Edinburgh
Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z)
- License Information
-
More Information
Article History
Received: 18 October 2023
Accepted: 23 August 2024
First Online: 10 September 2024
Declarations
:
: All components of Generation Scotland received ethical approval from the NHS Tayside Committee on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021), providing generic ethical approval for a wide range of uses within medical research. LBC1936 ethical approval was obtained from the Multicentre Research Ethics Committee for Scotland (Wave 1, MREC/01/0/56), the Lothian Research Ethics Committee (Wave 1, LREC/2003/2/29) and the Scotland A Research Ethics Committee (Waves 2–5, 07/MRE00/58). All participants provided written informed consent.
: Not applicable.
: R.E.M is an advisor to the Epigenetic Clock Development Foundation and has received consultant fees from Optima partners. A.M.M has previously received speaker’s fees from Illumina and Janssen and research grant funding from The Sackler Trust. R.F.H. has received consultant fees from Illumina and Optima partners. D.A.G. has received consultant fees from and is currently employed in part-time capacity by Optima partners. D.L.M. is currently employed in part-time capacity by Optima partners. P.W. reports grant income from Roche Diagnostics in relation to and outside of the submitted work, as well as grant income from AstraZeneca, Boehringer Ingelheim and Novartis, outside the submitted work and speaker fees from Novo Nordisk, and Raisio outside the submitted work. N.S. has consulted for Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer and Sanofi and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics outside the submitted work. All other authors declare no competing interest.
